# SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Source: https://onco.cc/trials/nct05814354/  
OnCo record `nct05814354` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Capecitabine, Eribulin, Gemcitabine and Paclitaxel / nab-paclitaxel in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial is a phase 3 interventional study registered as NCT05814354 by Jiangsu HengRui Medicine Co., Ltd., with 551 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2026-03-20. Interventions recorded: SHR-A1811 and Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05814354
- Phase: 3
- Setting: A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 551

## Sources

- ClinicalTrials.gov NCT05814354: https://clinicaltrials.gov/study/NCT05814354

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Eribulin](https://onco.cc/drugs/eribulin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05814354.json